Capnia, Inc., incorporated on August 25, 1999, is a healthcare company that develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company also has a therapeutics platform based on its technology for precision metering of gas flow. The Company's first commercial product, CoSense End-Tidal Carbon Monoxide (ETCO) Monitor, aids in the detection of excessive hemolysis, a condition in which red blood cells degrade rapidly. The Company also develops and markets pulmonary resuscitation solutions for the inpatient and ambulatory neonatal markets. The Company, through its subsidiary NeoForce, Inc., offers NeoPip T-piece resuscitator and related consumable, which delivers pre-set inspiratory pressure and positive end-expiratory pressures. Its other products include temperature probes, scales, surgical tables and patient surfaces.
The Company's therapeutic technology involves the use of metered nasal carbon dioxide (CO2) for the relief of symptoms related to various diseases. In addition, the Company is pursuing new initiatives for the development of this technology for the treatment of trigeminally mediated pain disorders, such as cluster headache and trigeminal neuralgia (TN). The Company's research and development efforts are focused on additional products based on its Sensalyze Technology Platform, a portfolio of methods and algorithms, which enables CoSense and can be applied to detect a range of analytes in exhaled breath, as well as other products for the neonatology market. Its development pipeline includes proposed diagnostic devices for asthma in children, assessment of blood CO2 concentration in neonates and malabsorption.
The Company's therapeutic technology consists of the use of nasal, non-inhaled CO2 for the treatment of the symptoms of allergy, as well as pain associated with migraine, cluster headache and TN. Serenz, its allergy therapeutic product candidate, is a treatment for symptoms related to Allergic Rhinitis (AR), which, when triggered by seasonal allergens, is commonly known as hay fever or seasonal allergies. CoSense is a point-of-care device that consists of a portable monitoring device and a single-use nasal cannula (Precision Sampling Set (PSS)). With CoSense data, physicians may be able to identify neonates with jaundice having risk of adverse neurological outcomes or other disability due to a high rate of hemolysis. Its Sensalyze Technology Platform allows the measurement of analytes in all patients, from neonates to adults, regardless of their ability to actively perform a breath maneuver.
The Company competes with GE Health Care, Fisher and Paykel, Philips, Draeger, Covidien, Masimo, Natus Medical, CAS Medical, Mercury Medical and CarFusion.
1235 Radio Rd Ste 110
The company headquarter is located in United States. The company was established in the 2024.| Ticker | CAPN |
| Long Name | Cayson Acquisition Corp Ordinary shares |
| Short Name | Cayson Acquisition Corp |